Navigation Links
Phase III Data on Safinamide in Parkinson’s Disease Presented,at American Academy of Neurology 59th Annual Meeting

dy and baseline of minus 2.2 ± 3.8 in the safinamide-treated group versus minus 1.2 ± 3.5 in the placebo group; p=0.0248; 95% CI=[-1.8;-0.1]).

Safinamide was also studied for effects on cognition. Compared with patients on dopamine agonist monotherapy, the addition of safinamide was associated with an improvement in cognitive function as shown by an improvement in tests assessing spatial working memory, strategic target detection and auditory number sequencing.

The side effects observed in the safinamide group were similar to those observed in the placebo group.

The trial was conducted in Europe, South America and Asia. A total of 270 early stage Parkinson’s disease patients (less than 5 years of disease) treated with a stable dose of a single dopamine agonist for at least 4 weeks were randomized to one of the three arms of the study to receive either safinamide at a dose of 50 to 100 mg once daily (90 patients), or safinamide at a dose of 150 to 200 mg once daily (90 patients) or matching placebo tablets (90 patients), as an add-on treatment to dopamine agonist therapy.

The higher safinamide dose-range of 150 to 200 mg per day did not offer any incremental advantage over safinamide 50 to 100 mg per day dose-range based on UPDRS scoring.

A one-year (52-week) extension phase of this study is ongoing. A second Phase III pivotal study of safinamide, in patients with mid-to-late stage Parkinson’s disease with motor fluctuations treated with a stable dose of levodopa, was initiated in November 2006.

Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson’s disease, Alzheimer’s disease, other cognitive disorders and restless leg syndrome, as per the agreement signed with Newron in October 2006.

1 The UPDRS is one of the mos
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:12/15/2014)... 2014 BerGenBio AS, a biopharmaceutical ... resistant cancers, today announces that it has raised NOK90 ... new and existing investors. BerGenBio will use ... of its pipeline of innovative cancer therapeutics, in particular ... candidate, BGB324, a first-in-class selective Axl kinase inhibitor, which ...
(Date:12/15/2014)... and Washington State are not the ... Oregon , Alaska , and ... November 2014 elections. Photo - http://photos.prnewswire.com/prnh/20141212/164152 ... The benefits of legalizing cannabis are manifold. There are ... tax revenue for state and local governments, in addition to ...
(Date:12/15/2014)...   DaVita HealthCare Partners Inc.  (NYSE: ... and most innovative health care communities, today announced ... Clinical Research  (DCR) and  HealthCare Partners Clinical Research , ... clinical research and data analytics services, specifically in ... renal disease (ESRD), as well as primary care ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2CannaInsider.com Estimates 200,000 New Jobs in the Cannabis Industry by 2015 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... GAITHERSBURG, Md., June 27, 2011 /PRNewswire-USNewswire / -- ... new service for people with Acute Lymphoblastic Leukemia ... refund eligible patients 100 percent of any co-pay ... information on eligibility criteria, please call 1-800-490-3262, Monday ...
... of two studies testing drugs to slow or stop ... newly diagnosed with type 1 diabetes will be presented ... in San Diego and simultaneously published online in the ... National Institutes of Health,s international network of researchers, Type ...
Cached Medicine Technology:Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia 2Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia 3Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia 4Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 2Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 3Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 4
(Date:12/15/2014)... Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first full-time ... providing evidence on the impact of 100% pure fruit ... enough evidence already exists showing a negative link between ... the onset of tooth decay. One question that has ... fruit juice, meaning it is completely natural with no ...
(Date:12/15/2014)... OutMarket , a provider of ... Media Cheat Sheets ,” a guide that exposes the ... on the top ten social media networks. , ... awareness, engagement, and customer service. It can also increase ... impact on new networks and weather constantly changing algorithms, ...
(Date:12/15/2014)... -- Expert pilots process visual information more efficiently than ... decisions during landings, a new study shows. Landing ... to master, and 36 percent of all airplane crashes ... approach and landing. Researchers monitored the brain activity ... while they were at the controls of a flight ...
(Date:12/15/2014)... December 15, 2014 Emergo Group, Inc., ... 26 countries in North and South America, Europe, the ... from industry participants for its 2015 Medical Device Industry ... to identify upcoming business and market trends as well ... The survey targets areas including:, , ...
(Date:12/15/2014)... 15, 2014 Bacteroides is becoming the indicator ... it much more prevalent than coliforms, it cannot reproduce in ... environment. , Key Benefits of the new Bacteroides Sewage ... , Eliminates false positives from coliforms naturally occurring ... , Maintain the same sampling method with ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... Neurosurgeons from NYU Langone Medical Center will present research ... to treat neurosurgical conditions at the annual meeting of ... 14-18, 2012 in Miami Beach, FL. NYU Langone faculty ... at AANS, including: *Craino-Cervical and C1C2 Stabilization ...
... Virginia Commonwealth University School of Medicine researchers have discovered ... may contribute to high blood pressure and increase susceptibility to ... findings could provide clues to the best treatment approaches for ... can block blood flow to a pregnant woman,s internal organs ...
... Steven Reinberg HealthDay Reporter , THURSDAY, April ... called phthalates, which are found in soaps, lotions, plastics ... diabetes among older adults, Swedish researchers say. "Our ... contribute to the development of diabetes," said lead researcher ...
... , THURSDAY, April 12 (HealthDay News) -- Genetic evidence ... a new study says. The finding is significant because ... not, the researchers explained. The researchers compared the number ... life-cycle stage of head and body lice and found that ...
... in how exercise affects menopausal women, according to Penn ... one experiences more hot flashes after physical activity, while ... that seemed to differentiate the two groups was perceived ... of kinesiology. "These women have ways of dealing with ...
... Dotinga HealthDay Reporter , THURSDAY, April 12 (HealthDay ... stress, a new study from Denmark finds that the marriages ... likely to fall apart. The study debunks "a persistent ... one,s marriage and family. This is simply not true," said ...
Cached Medicine News:Health News:NYU Langone experts present research, clinical advances at neurosurgeons meeting 2Health News:Changes in gene expression may help explain high blood pressure in pregnancy 2Health News:Common Plastics Chemical Might Boost Diabetes Risk 2Health News:Common Plastics Chemical Might Boost Diabetes Risk 3Health News:Exercise and attitude may be thermostat for hot flashes 2Health News:Parents of Kids With Cancer No More Likely to Break Up 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: